Are there generic versions of Canafenib? Domestic and foreign generic drug research and development and accessibility analysis

Encorafenib is a targeted drug mainly used to treat melanoma carrying BRAF V600E mutation, especially when used in combination with bemetinib (binimetinib). This drug prevents the proliferation of tumor cells by inhibiting the abnormal activity of the BRAF mutated gene, and has been marketed in many countries and regions such as Europe and the United States. However, in China, canafenib has not yet been approved for marketing, so domestic patients cannot purchase it directly through formal channels.

Although the original drug of canafenib (Braftovi) has not yet been launched in China, its sales and application are relatively mature around the world, especially in the European and American markets. According to international drug pricing information, the European version of canafenib is priced higher. Usually, the prices of 75mg*42 capsules and 75mg*168 capsules are about more than 10,000 yuan and more than 40,000 yuan respectively. The specific prices will fluctuate due to exchange rate fluctuations. This places a high financial burden on many patients.

Currently, Canafenib has not yet launched generic drugs in the Chinese market, but a few foreign generic drugs have entered the market, including those produced in Laos. The Laotian version of the generic version of Canafenib is 75mg*90 tablets, and the price is about 4,000 yuan, which is significantly lower than the price of the original drug. The ingredients of these generic drugs are basically the same as those of the original drugs, so their therapeutic effects and safety are comparable to those of the original drugs.

Generally speaking, generic drugs of canafenib are currently mainly produced in a few countries such as Laos, and have obvious price advantages. For domestic patients, although they face higher purchase costs and difficulties in access, with the progress of generic drug research and development, the accessibility of canafenib may improve in the future. In this process, the improvement of the domestic drug approval system and the optimization of medical insurance policies may also provide more affordable treatment options for more patients.

Reference materials:https://www.braftovi.com/